Quoin Pharmaceuticals (NASDAQ:QNRX) Now Covered by Craig Hallum

Equities researchers at Craig Hallum assumed coverage on shares of Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) in a report released on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $16.00 price target on the stock. Craig Hallum‘s price objective suggests a potential upside of 376.19% from the stock’s current price.

Several other research analysts have also weighed in on the stock. Wall Street Zen lowered shares of Quoin Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 15th. BTIG Research assumed coverage on shares of Quoin Pharmaceuticals in a research note on Monday, October 12th. They issued a “buy” rating and a $14.00 target price for the company. Lake Street Capital began coverage on shares of Quoin Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “buy” rating and a $20.00 target price on the stock. Weiss Ratings raised shares of Quoin Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, November 12th. Finally, Canaccord Genuity Group assumed coverage on shares of Quoin Pharmaceuticals in a report on Monday, October 19th. They issued a “buy” rating and a $18.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Quoin Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Check Out Our Latest Report on QNRX

Quoin Pharmaceuticals Stock Performance

NASDAQ:QNRX opened at $3.36 on Friday. Quoin Pharmaceuticals has a 12-month low of $3.25 and a 12-month high of $23.50. The stock’s fifty day simple moving average is $4.71 and its 200-day simple moving average is $5.69.

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.52) by $0.55. On average, equities analysts anticipate that Quoin Pharmaceuticals will post -7.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Anthony Culverwell purchased 6,146 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, August 31st. The stock was bought at an average price of $4.88 per share, for a total transaction of $29,992.48. Following the completion of the acquisition, the director directly owned 40,364 shares of the company’s stock, valued at $196,976.32. This represents a 17.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Myers acquired 20,490 shares of the stock in a transaction dated Monday, August 31st. The shares were bought at an average cost of $4.88 per share, with a total value of $99,991.20. Following the transaction, the chief executive officer directly owned 37,713 shares of the company’s stock, valued at $184,039.44. This represents a 118.97% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 57,370 shares of company stock valued at $279,966 in the last quarter. 7.54% of the stock is owned by company insiders.

Hedge Funds Weigh In On Quoin Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC lifted its holdings in shares of Quoin Pharmaceuticals by 237.5% in the third quarter. AIGH Capital Management LLC now owns 236,234 shares of the company’s stock valued at $1,077,000 after purchasing an additional 166,234 shares in the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Quoin Pharmaceuticals during the third quarter worth about $1,077,000. Finally, SummitTX Capital L.P. grew its holdings in shares of Quoin Pharmaceuticals by 54.8% during the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after buying an additional 35,505 shares in the last quarter. 8.63% of the stock is owned by institutional investors and hedge funds.

Quoin Pharmaceuticals Company Profile

(Get Free Report)

Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin. Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.

Further Reading

Analyst Recommendations for Quoin Pharmaceuticals (NASDAQ:QNRX)

Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.